Mimotopes and Genzyme Pharmaceuticals to collaborate
Friday, 27 January, 2006
PharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
The exclusive and global agreement commences on February 1, 2006.
Mimotopes will supply customers with research grade peptides and related services up to the point of lead candidate identification in pre-clinical applications.
Genzyme Pharmaceuticals, a business unit of Genzyme Corporation that develops and manufactures peptide and lipid products, will supply customers with identified lead candidate peptides for pre-clinical applications through to clinical and therapeutic grade peptides and related services.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
